Intervention group for Hysterectomy, Vaginal

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Wake Forest University Health Sciences, Winston-Salem, NC
Hysterectomy, Vaginal
Miyamodel Training - Other
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

Simulation training with the Miya Model will improve Operating Room performance of Vaginal Hysterectomy (VH) in novice surgeons and this phase of the study is designed to test that.

Treatment Effectiveness

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Month 2

Month 2
Vaginal Surgical Skills Index (VSSI) scores - Control Group
Vaginal Surgical Skills Index (VSSI) scores - Intervention Group

Trial Safety

Trial Design

2 Treatment Groups

Control group
1 of 2
Intervention group
1 of 2
Active Control
Experimental Treatment

70 Total Participants · 2 Treatment Groups

Primary Treatment: Intervention group · No Placebo Group · N/A

Intervention group
Other
Experimental Group · 1 Intervention: Miyamodel Training · Intervention Types: Other
Control groupNoIntervention Group · 1 Intervention: Control group · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: month 2
Closest Location: Wake Forest University Health Sciences · Winston-Salem, NC
2008First Recorded Clinical Trial
1 TrialsResearching Hysterectomy, Vaginal
417 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are a resident of a participating institution.\n
You have had two or fewer vaginal hysterectomies.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.